Cargando…

Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes

BACKGROUND: Spondylodiscitis is a rare illness and serious complication of the vertebral column. The suitable type of surgery is debatable for these patients. This study describes a series of cases that are treated with modified interbody fusion for the treatment of spondylodiscitis by combining all...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezvani, Majid, Zohrevand, Amirhosein, Azimi, Parisa, Fallahpour, Soheil, Saghaei, Saeid, Yazdanian, Taravat, Pashnehtalaee, Mohammadjavad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878893/
https://www.ncbi.nlm.nih.gov/pubmed/36741477
http://dx.doi.org/10.22088/cjim.14.1.133
_version_ 1784878585420447744
author Rezvani, Majid
Zohrevand, Amirhosein
Azimi, Parisa
Fallahpour, Soheil
Saghaei, Saeid
Yazdanian, Taravat
Pashnehtalaee, Mohammadjavad
author_facet Rezvani, Majid
Zohrevand, Amirhosein
Azimi, Parisa
Fallahpour, Soheil
Saghaei, Saeid
Yazdanian, Taravat
Pashnehtalaee, Mohammadjavad
author_sort Rezvani, Majid
collection PubMed
description BACKGROUND: Spondylodiscitis is a rare illness and serious complication of the vertebral column. The suitable type of surgery is debatable for these patients. This study describes a series of cases that are treated with modified interbody fusion for the treatment of spondylodiscitis by combining allograft and autograft bone chips with posterior segmental fusion. METHODS: This was a retrospective study. The clinical deficit was evaluated with ASIA, VAS, and JOABPEQ scores before and after surgery. Radiological parameters were assessed with local kyphosis angle (degree), segmental height correction, and loss of correction. Post-operative bone union was evaluated as suggested by Tan et al. RESULTS: The mean age of patients (n=34) was 52.3(SD=13.6) years and 67.6% were males. The mean follow-up duration was 25.8 (2.3) months. In the last follow-up, VAS back pain 4.9(0.77), VAS leg pain 4.6(0.78), JOABPEQ low back pain 68.1 (9.3), JOABPEQ lumbar function 81.3 (8.9), and JOABPEQ walking ability 72.8 (8.3) shows a significant difference when compared with preoperative scores. According to ASIA grading, none of the patients deteriorated neurologically (all p<0.0001). The average segmental height correction and loss of correction were observed 7.5(3.7) % and -1.8(3.6) %, respectively, indicating improvements in the patients. A high union fusion rate (82.4%) was observed in the last follow-up. CONCLUSION: This modified method can be a safe and effective technique for surgical intervention in patients with spondylodiscitis.
format Online
Article
Text
id pubmed-9878893
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-98788932023-02-03 Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes Rezvani, Majid Zohrevand, Amirhosein Azimi, Parisa Fallahpour, Soheil Saghaei, Saeid Yazdanian, Taravat Pashnehtalaee, Mohammadjavad Caspian J Intern Med Short Communication BACKGROUND: Spondylodiscitis is a rare illness and serious complication of the vertebral column. The suitable type of surgery is debatable for these patients. This study describes a series of cases that are treated with modified interbody fusion for the treatment of spondylodiscitis by combining allograft and autograft bone chips with posterior segmental fusion. METHODS: This was a retrospective study. The clinical deficit was evaluated with ASIA, VAS, and JOABPEQ scores before and after surgery. Radiological parameters were assessed with local kyphosis angle (degree), segmental height correction, and loss of correction. Post-operative bone union was evaluated as suggested by Tan et al. RESULTS: The mean age of patients (n=34) was 52.3(SD=13.6) years and 67.6% were males. The mean follow-up duration was 25.8 (2.3) months. In the last follow-up, VAS back pain 4.9(0.77), VAS leg pain 4.6(0.78), JOABPEQ low back pain 68.1 (9.3), JOABPEQ lumbar function 81.3 (8.9), and JOABPEQ walking ability 72.8 (8.3) shows a significant difference when compared with preoperative scores. According to ASIA grading, none of the patients deteriorated neurologically (all p<0.0001). The average segmental height correction and loss of correction were observed 7.5(3.7) % and -1.8(3.6) %, respectively, indicating improvements in the patients. A high union fusion rate (82.4%) was observed in the last follow-up. CONCLUSION: This modified method can be a safe and effective technique for surgical intervention in patients with spondylodiscitis. Babol University of Medical Sciences 2023 /pmc/articles/PMC9878893/ /pubmed/36741477 http://dx.doi.org/10.22088/cjim.14.1.133 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Rezvani, Majid
Zohrevand, Amirhosein
Azimi, Parisa
Fallahpour, Soheil
Saghaei, Saeid
Yazdanian, Taravat
Pashnehtalaee, Mohammadjavad
Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes
title Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes
title_full Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes
title_fullStr Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes
title_full_unstemmed Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes
title_short Autograft and allograft bone chips interbody fusion for spondylodiscitis: Surgery outcomes
title_sort autograft and allograft bone chips interbody fusion for spondylodiscitis: surgery outcomes
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878893/
https://www.ncbi.nlm.nih.gov/pubmed/36741477
http://dx.doi.org/10.22088/cjim.14.1.133
work_keys_str_mv AT rezvanimajid autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes
AT zohrevandamirhosein autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes
AT azimiparisa autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes
AT fallahpoursoheil autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes
AT saghaeisaeid autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes
AT yazdaniantaravat autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes
AT pashnehtalaeemohammadjavad autograftandallograftbonechipsinterbodyfusionforspondylodiscitissurgeryoutcomes